Bellerophon Therapeutics, Inc.
bellerophon.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed Nov 14, 2023. Its latest SEC filing is a 15-12G from Mar 6, 2024.
10-Q for Q3 FY2023, filed Nov 14, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Develops a pulsed inhaled nitric oxide therapy and portable delivery system for patients with pulmonary hypertension associated with lung diseases.
10-K for FY2022, filed Mar 31, 2023
How Did They Make Money?
No revenue was reported.
10-K for FY2022, filed Mar 31, 2023
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2023, filed Nov 14, 2023
−$1.9MView ↗
- ▼ −62% (Loss)
- vs −$5.1M in Q3 FY2022
-
Mar 4, 2024
Stockholders approved the company’s liquidation and dissolution
The approval authorizes the board to liquidate and dissolve the company under its plan.
Sources
8-K, filed Mar 4, 2024
The Company’s stockholders approved the liquidation and dissolution of the Company and the Plan of Liquidation and Dissolution, which…View ↗
-
Nov 21, 2023
CEO and finance chief departed; new principal executive took over
Peter Fernandes left, and Craig Jalbert was appointed president and principal executive, financial and accounting officer.
Sources
8-K, filed Nov 21, 2023
Pursuant to the previously disclosed transition and separation agreements between Bellerophon Therapeutics, Inc. (the “Company”) and each…View ↗
-
Oct 13, 2023
Board approved a dissolution plan as Nasdaq moved to delist the shares
The board approved the plan subject to stockholder approval; Nasdaq said trading would be suspended after the company could not meet continued-listing conditions.
Sources
8-K, filed Oct 13, 2023
As previously disclosed, on July 19, 2023, the Nasdaq Listing Qualifications staff (“Staff”) notified Bellerophon Therapeutics, Inc. (the…View ↗
COVID treatment program ended
The earlier report described emergency access for INOpulse in hospitalized patients and plans to seek broader access; the latest says the COVID treatment study was permanently halted and no further studies are planned.
10-K for FY2019, filed Apr 6, 2020 10-K for FY2022, filed Mar 31, 2023On March 19, 2020, the FDA granted emergency expanded access to allow for INOpulse to immediately be used as supportive treatment for a…View ↗
On March 19, 2020, the FDA granted emergency expanded access (“EA”) to allow for our INOpulse system to immediately be used as supportive…View ↗
Loading...
